Home/Stocks/EW
Public stock intelligence

Edwards Lifesciences Corporatio with price, financials, news flow, and insider context in one page.

Edwards Lifesciences Corporatio is being tracked here through price action, operating context, and headline flow. This public page covers the latest market move, where EW sits inside Healthcare and Medical Devices, and the key financial markers that matter before moving into a fuller research workflow.

HealthcareMedical DevicesNYQUnited States
Live price
$81.08
Session move
+1.69% today
Next earnings
Jul 23, 2026
Market cap
46.66B
Volume
4.97M
52-week range
56% through the 52-week range
Forward P/E
24.09
Revenue growth
16.7%
Dividend yield
N/A
Price history
Daily closes for EW, with a quick range selector for public research.
About the company

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Employees
16,000
Beta
0.87
ROE
10.5%
Current ratio
4.42
Visit company website
Research framing

This page is structured for research context, not a trade call. It gives you a clean read on where EW sits in its range, what the last few quarters look like, and which headlines are shaping attention.

For position sizing, alerts, saved watchlists, and deeper analysis workflows, the next step is the logged-in Meridian workspace.

Quarterly financials
QuarterRevenueNet incomeFree cash flow
Q4 20251.57B91.2M353.5M
Q3 20251.55B291.1M516.2M
Q2 20251.53B329.8M240.9M
Q1 20251.41B358M224.4M
Insider activity
ULLEM SCOTT B
Chief Financial Officer
May 11, 2026
Transaction
D
Value
N/A
ZOVIGHIAN BERNARD J
Chief Executive Officer
May 11, 2026
Transaction
Stock Gift at price 0.00 per share.
Value
N/A
MARKOWITZ WAYNE
Officer
May 11, 2026
Transaction
Sale at price 79.73 per share.
Value
47.28K
LAVIOLETTE PAUL A
Director
May 8, 2026
Transaction
Stock Award(Grant) at price 0.00 per share.
Value
N/A
FEINBERG DAVID T
Director
May 8, 2026
Transaction
Stock Award(Grant) at price 0.00 per share.
Value
N/A
GALLAHUE KIERAN T.
Director
May 8, 2026
Transaction
Stock Award(Grant) at price 0.00 per share.
Value
N/A
Why this page ranks

A public stock page should answer the first research questions before asking for a signup.

This EW page is designed for public research utility. You can read the latest session move, check the one-year chart, review a compact financial table, scan recent headlines, and compare adjacent names without immediately moving into a gated dashboard.

The logged-in Meridian workflow goes further with saved watchlists, deeper analysis, alert routing, and recurring review systems. The public layer is meant to be credible and indexable on its own, not a hollow teaser page.